About the gut microbiome as a pharmacological target in atherosclerosis

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)


The contribution of intestinal bacterial strains (gut microbiota) in the development of cardiometabolic disease is increasingly recognized as potential diagnostic and pharmacological target. Changes in the intestinal bacterial composition and subsequent altered diversity has been associated with presence of chronic low-grade inflammation of mesenteric visceral adipose tissue, a known feature of malign obesity which can eventually lead to insulin resistance and type 2 diabetes mellitus. However, causality still needs to be proven. In this regard, both fecal transplantation studies as well as multiethnic prospective cohorts can help to identify the causally involved driving intestinal bacterial strains in human cardiometabolism. Ultimately, it is expected that novel diagnostic markers as well as therapeutics (pharmabiotics and vaccine strategies) can be developed
Original languageEnglish
Pages (from-to)75-78
JournalEuropean journal of pharmacology
Issue numberPart A
Publication statusPublished - 2015

Cite this